Trials / Recruiting
RecruitingNCT07236099
Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of the Efficacy and Safety of ICP-332 in Participants With Prurigo Nodularis
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 135 (estimated)
- Sponsor
- Beijing InnoCare Pharma Tech Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
Evaluate the efficacy and safety of ICP-332 in participants with Prurigo Nodularis (PN)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ICP-322 | ICP-322 Tablets |
| DRUG | Placebo | ICP-332 Placebo Tablets |
Timeline
- Start date
- 2025-11-27
- Primary completion
- 2027-03-01
- Completion
- 2027-10-01
- First posted
- 2025-11-19
- Last updated
- 2026-04-09
Locations
16 sites across 2 countries: United States, China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT07236099. Inclusion in this directory is not an endorsement.